Trial Profile
Phase I/II Study of Safety and Efficacy of Tofacitinib Combined With Chidamide in Patients With Relapsed and Refractory Extranodal Natural Killer/T Cell Lymphoma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Tucidinostat (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- 02 Aug 2018 New trial record